Get the Stockscreener App
3.02
7.86%
0.22
Compass Therapeutics Inc stock is traded at $3.02, with a volume of 1.45M.
It is up +7.86% in the last 24 hours and down -1.63% over the past month.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
See More
Previous Close:
$2.80
Open:
$2.79
24h Volume:
1.45M
Relative Volume:
1.51
Market Cap:
$417.61M
Revenue:
-
Net Income/Loss:
$-45.44M
P/E Ratio:
-8.6286
EPS:
-0.35
Net Cash Flow:
$-42.28M
1W Performance:
+1.68%
1M Performance:
-1.63%
6M Performance:
+3.42%
1Y Performance:
+153.78%
1-Day Range:
$2.79
$3.05
1-Week Range:
$2.66
$3.05
52-Week Range:
$1.19
$4.08
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
3.02 | 396.87M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Apr-02-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Heatmap Data Shows High Activity in Compass Therapeutics Inc. SectorWeekly Trend Recap & Safe Entry Zone Identification - thegnnews.com
Can Compass Therapeutics Inc. Outperform Peers After Recent PullbackJuly 2025 Big Picture & Free Reliable Trade Execution Plans - classian.co.kr
Will Volume Confirm Reversal in Compass Therapeutics Inc.2025 Year in Review & Entry and Exit Point Strategies - newsyoung.net
Compass Therapeutics (CMPX) Rated ‘Outperform’ amid Clinical Pipeline Development - sg.finance.yahoo.com
Trend analysis for Compass Therapeutics Inc. this weekJuly 2025 Analyst Calls & Free Daily Entry Point Trade Alerts - Newser
What’s the RSI of Compass Therapeutics Inc. stockWeekly Gains Summary & Community Shared Stock Ideas - thegnnews.com
What analysts say about Compass Therapeutics Inc. stock outlook2025 Trading Volume Trends & Real-Time Buy Signal Notifications - Newser
Will Compass Therapeutics Inc. bounce back from current supportWeekly Profit Analysis & Free Daily Entry Point Trade Alerts - Newser
Using Ichimoku Cloud for Compass Therapeutics Inc. technicalsWeekly Stock Summary & Free Weekly Chart Analysis and Trade Guides - Newser
Regression Model Predicts Rangebound Movement in Compass Therapeutics Inc.Analyst Downgrade & Low Risk High Reward Trade Ideas - beatles.ru
Compass Therapeutics Inc. stock prediction for this weekTrade Ideas & Safe Swing Trade Setup Alerts - Newser
Is Compass Therapeutics Inc. stock bottoming outWeekly Market Outlook & Momentum Based Trading Ideas - Newser
Multi asset correlation models including Compass Therapeutics Inc.Portfolio Value Report & Free Safe Entry Trade Signal Reports - Newser
Using data filters to optimize entry into Compass Therapeutics Inc.Insider Buying & Safe Capital Allocation Plans - Newser
Will Compass Therapeutics Inc. stock go up soon2025 Pullback Review & Long Hold Capital Preservation Tips - Newser
What to expect from Compass Therapeutics Inc. in the next 30 daysGlobal Markets & Proven Capital Preservation Tips - Newser
How to read the order book for Compass Therapeutics Inc.July 2025 Volume & Verified High Yield Trade Plans - Newser
Is a relief rally coming for Compass Therapeutics Inc. holdersMarket Performance Summary & Accurate Intraday Trading Signals - Newser
Has Compass Therapeutics Inc. formed a bullish divergenceM&A Rumor & AI Enhanced Market Trend Forecasts - Newser
Is Compass Therapeutics Inc. forming a bottoming baseSell Signal & Real-Time Buy Zone Alerts - Newser
Compass Therapeutics dips 5%, prices $120M stock - MSN
Compass Therapeutics Inc. stock retracement – recovery analysis2025 Pullback Review & Expert Curated Trade Ideas - Newser
News impact scoring models applied to Compass Therapeutics Inc.July 2025 Intraday Action & Expert Verified Movement Alerts - Newser
Heatmap analysis for Compass Therapeutics Inc. and competitors2025 Market Sentiment & Free Technical Confirmation Trade Alerts - Newser
Compass Therapeutics Receives 'Buy' Rating Reaffirmation from D. Boral Capital - AInvest
Compass Therapeutics Raises $112.5M in Public Offering - AInvest
HC Wainwright Analysts Decrease Earnings Estimates for CMPX - Defense World
Compass Therapeutics Announces Public Offering to Raise $112.5M - MSN
Earnings Chart Overlay Points to Compass Therapeutics Inc. UpsideMarket Trend Report & Growth Focused Stock Reports - thegnnews.com
Wedbush Forecasts Lower Earnings for Compass Therapeutics - Defense World
Compass Therapeutics Reports Q2 2025 Financials and Clinical Progress - MSN
Compass Therapeutics price target raised to $12 from $10 at Guggenheim - MSN
Compass Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - AInvest
We are now beginning of Q3 2025, how following data readout was completed on Q4 2025? - AInvest
Who are the investors of CMPX - AInvest
Compass Therapeutics And 2 Other Promising Penny Stocks To Consider - Yahoo Finance
Compass Therapeutics shares rise 2.21% intraday after announcing a $120 million upsized public offering. - AInvest
Real Time Data Flags Unusual Activity in Compass Therapeutics Inc.2025 Breakouts & Breakdowns & AI Enhanced Execution Alerts - sundaytimes.kr
Compass Therapeutics sells $120M in stock; RemeGen to seek China approval - Endpoints News
Compass Therapeutics: Finding Their Way With More Positive Updates In BTC - Seeking Alpha
Compass Therapeutics Posts Wider Q2 Loss - AOL.com
Compass, Inc. shares rise 2.48% premarket after Compass Therapeutics announced a $120 million public offering. - AInvest
Compass Therapeutics Announces $120M Stock Offering, Prices Shares at $3.00 - AInvest
Compass Therapeutics Faces Financial Risks Amid Global Economic Uncertainty and Trade Tensions - MSN
Compass Therapeutics (NASDAQ:CMPX) Receives Buy Rating from D. Boral Capital - Defense World
Guggenheim Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock Price - Defense World
Compass Therapeutics Announces Proposed Public Offering - GlobeNewswire
Compass Therapeutics' $120M Equity Raise: A Strategic Move for Pipeline Advancement or a Dilution Risk? - AInvest
Compass Therapeutics prices $120 million public offering of common stock By Investing.com - Investing.com Canada
Compass Therapeutics prices $120 million public offering of common stock - Investing.com
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering - The Manila Times
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Compass Therapeutics Inc Stock (CMPX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
| ORBIMED ADVISORS LLC | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):